Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0PLDYL
ADC Name	1959-sss/DM4
Synonyms	1959-sss-DM4; 1959-sss DM4 Click to Show/Hide
Drug Status	Investigative
Indication	In total 1 Indication(s) Glioblastoma [ICD11:2A00] Investigative
Drug-to-Antibody Ratio	2
	3D MOL	2D MOL
Antibody Name	Undisclosed
Antigen Name	Galectin-3-binding protein (LGALS3BP)		Antigen Info
Payload Name	Mertansine DM4		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	Undisclosed

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 89.57	%	Gch6 cells	Glioblastoma

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	1.02	nM	Gch14 cells	Glioblastoma
Half Maximal Inhibitory Concentration (IC50)	1.57	nM	Gch6 cells	Glioblastoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 89.57% (Day 30)	High LGALS3BP expression (LGALS3BP +++)
Method Description	Gch6 cell xenograft mice were intravenously treated with 10 mg/kg 1959-sss/DM4 twice weekly for a total of three injections.
In Vivo Model	Gch6 CDX model
In Vitro Model	Glioblastoma	Gch6 cells		Homo sapiens

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.02 nM	High LGALS3BP expression (LGALS3BP +++)
Method Description	In vitro cytotoxicity of ADCs against a panel of four multiple human glioblastoma cell lines.
In Vitro Model	Glioblastoma	Gch14 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.57 nM	High LGALS3BP expression (LGALS3BP +++)
Method Description	In vitro cytotoxicity of ADCs against a panel of four multiple human glioblastoma cell lines.
In Vitro Model	Glioblastoma	Gch6 cells		Homo sapiens

References

Ref 1	Extracellular LGALS3BP: a potential disease marker and actionable target for antibody-drug conjugate therapy in glioblastoma. Mol Oncol. 2023 Aug;17(8):1460-1473. doi: 10.1002/1878-0261.13453. Epub 2023 Jun 7.